Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
- Sponsor:
- SWOG
- Sponsor Study ID:
- S2206
- CTO #:
- 104019
- NCT Number:
- NCT06058377
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Breast
- Study Objectives:
- To compare breast cancer event-free survival between participants randomized to standard of care neoadjuvant chemotherapy alone versus standard of care neoadjuvant chemotherapy concurrent with durvalumab.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Sivapiragasam, Abirami, at sivapira@musc.edu .
- Study Coordinator, Gelardi, Theresa, at gelardi@musc.edu .
-
Tidelands Health
- Affiliate Principal Investigator, Milling, Lee, at leemilling@gmail.com .
- Study Coordinator, Roe, Barbara, at broe@tidelandshealth.org .
- Study Coordinator, DeNunzio, Cara, at cdenunzio@tidelandshealth.org .
Trial opened at the following institutions:
Tidelands Health, Medical University of South Carolina